Cholesteryl ester hydroperoxide lability is a key feature of the oxidative susceptibility of small, dense LDL

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 3, 1999, Pages 810-820

  Chancharme, Laurent ^a   Thérond, Patrice ^b   Nigon, Fabienne ^a   Lepage, Sylvie ^a   Couturier, Martine ^b   Chapman, M John ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b BICÊTRE HOSPITAL   (France)

Author keywords

Cholesteryl ester hydroperoxides; LDL subclasses; Lipophilic antioxidants; Polyunsaturated fatty acids; Reversed phase high performance liquid chromatography

Indexed keywords

CHOLESTEROL DERIVATIVE; CHOLESTEROL ESTER; LIPID HYDROPEROXIDE; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID DERIVATIVE;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; HUMAN; HYPERLIPOPROTEINEMIA; LIPID ANALYSIS; LIPID OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

EID: 0345391027     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.3.810     Document Type: Article

References (66)

1. Small DM. Progression and regression of atherosclerotic lesions: insights from lipid physical biochemistry. Arteriosclerosis. 1988;8:103-129.
2. Harland WA, Crilbert TD, Brooks CJW. Lipids of human atheroma, VIII: oxidised derivatives of cholesteryl linoleate. Biochim Biophys Acta. 1973; 316:378-385.
3. Suarna C, Dean RT, May J, Stocker R. Human atherosclerotic plaques contain both oxidized and relatively large amounts of α-tocopherol and ascorbate. Arterioscler Thromb Vasc Biol. 1995;15:1616-1624.
4. Smith EB. The relationship between plasma and tissue lipids in human atherosclerosis. Adv Lipid Res. 1974;12:1-49.
5. Consensus Conference G. Lowering blood cholesterol to prevent heart disease. JAMA. 1985;253:2080-2086.
6. Krauss RM. Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr Opin Lipidol. 1994;5:339-349.
7. Chapman MJ, Guerin M, Bruckert E. Atherogenic, dense low-density lipoproteins: pathophysiology and new therapeutic approaches. Eur Heart J. 1998;19:A24-A30.
8. Tornvall P, Karpe F, Carlson LA, Hamsten A. Relationship of low density lipoprotein subfractions to angiographically-defined coronary disease in young survivors of myocardial infarction. Atherosclerosis. 1991;90: 67-80.
9. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willet WC, Krauss RM. Low density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988;260:1917-1925.
10. Sniderman A, Shapiro S, Marpole D, Skinner B, Teng B, Kwiterovich PO. Association of coronary atherosclerosis with hyperapobetalipoproteinemia (increased but normal cholesterol levels in human low-density lipoproteins). Proc Natl Acad Sci U S A. 1980;77:604-608.
11. Swinkels DW, Demacker PNM, Hendricks JCM, Brenninnkmeijer BJ, Stuyt PMJ. The relevance of a protein-enriched low density lipoprotein as a risk for coronary heart disease in relation to other known factors. Atherosclerosis. 1989;77:59-66.
12. Griffin BA, Freeman DJ, Tait GW, Thomson J, Caslake MJ, Packard CJ, Shepherd J. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis. 1994;106: 241-253.
13. Crouse JR, Parks JS, Schey HM, Kahl FR. Studies of low density lipoprotein molecular weight in human beings with coronary artery disease. J Lipid Res. 1985;26:566-573.
14. Campos H, Genest JJ, Blijlevens E, McNamara JR, Jenner JL, Ordovas JM, Wilson PWF, Schaefer EJ. Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb. 1992;12:187-195.
15. Shen MS, Krauss RM, Lindgren FT, Forte TM. Heterogeneity of serum low density lipoproteins in normal human subjects. J Lipid Res. 1981; 22:236-244.
16. Chapman MJ, Laplaud MP, Gerald L, Forgez P, Bruckert E, Goulinet S, Lagrange D. Further resolution of the low-density lipoprotein spectrum in normal human plasma: physicochemical characteristics of discrete subspecies separated by density gradient ultracentrifugation. J Lipid Res. 1988;29:442-458.
17. Packard CJ, Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol. 1997;17:3542-3556.
18. Tribble DL, Van Der Berg JJM, Motchnik PA, Ames BN, Lewis DM, Chait A, Krauss RM. Oxidative susceptibility of low density lipoprotein subfractions is related to their ubiquinol-10 and α-tocopherol content. Proc Natl Acad Sci U S A. 1994;1994:1183-1187.
19. Goulinet S, Chapman MJ. Plasma LDL and HDL subspecies are heterogenous in particle content of tocopherols and oxygenated and hydrocarbon carotenoids. Arterioscler Thromb Vasc Biol. 1997;17:786-796.
20. Tsoukatos DC, Arborati M, Liapikos T, Clay KL, Murphy RC, Chapman MJ, Ninio E. Copper-catalyzed oxidation mediates PAF formation in human LDL subspecies. Arterioscler Thromb Vasc Biol. 1997;17: 3505-3512.
21. Nigon F, Lesnik P, Rouis M, Chapman MJ. Discrete subspecies of human low density lipoproteins are heterogenous in their interaction with the cellular LDL receptor. J Lipid Res. 1991;32:1741-1753.
22. Anber V, Millar JS, McConnel M, Shepherd J, Packard CJ. Interaction of very low density, intermediate density, and low density lipoproteins with human arterial wall proteoglycans. Arterioscler Thromb Vasc Biol. 1997; 17:2507-2514.
23. Hurt-Camejo E, Camejo G, Rosengren B, Lopez F, Wiklund O, Bondjers G. Differential uptake of proteoglycan-selected subfractions of low density lipoprotein by human macrophages. J Lipid Res. 1990;31: 1387-1398.
24. Hurt-Camejo E, Camejo J, Rosengren B, Lopez F, Ahlström C, Fager G, Bondjers G. Effect of arterial proteoglycans and glycosaminoglycans on low density lipoprotein oxidation and its uptake by human macrophages and arterial smooth muscle cells. Arterioscler Thromb. 1992;12:569-583.
25. de Graaf J, Hak-Lemmers HLM, Hectors MPC, Demacker PNM, Hendricks JCM, Stalenhoef AFH. Enhanced susceptibility to in vitro oxidation of the low density lipoprotein subfraction in healthy men. Arterioscler Thromb. 1991;11:298-306.
26. Dejager S, Bruckert E, Chapman MJ. Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia. J Lipid Res. 1993;34:295-308.
27. Tribble DL, Holl LG, Wood PD, Krauss RM. Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis. 1992;93:189-199.
28. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320:915-924.
29. Esterbauer H, Rotheneder M, Striegl G, Waeg G, Ashy A, Sattler W, Jurgens G. Vitamin E and other lipophilic antioxidants protect LDL against oxidation. Fat Sci Technol. 1989;8:316-324.
30. Esterbauer H, Striegl G, Puhl H, Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun. 1989;6:67-75.
31. Esterbauer H, Jürgens G, Quehenberger O, Koller E. Autoxidation of human low density lipoprotein: loss of polyunsaturated fatty acids and vitamin E and generation of aldehydes. J Lipid Res. 1987;28:495-509.
32. Chapman MJ, Goldstein S, Lagrange D, Laplaud MP. A density gradient ultracentrifugal procedure for isolation of the major lipoprotein classes from human serum. J Lipid Res. 1981;22:339-358.
33. Abell LL, Levy BB, Brodie BB, Kendall FE. A simplified method for the estimation of total cholesterol in serum and demonstration of its specificity. J Biol Chem. 1952;195:357-362.
34. Kessler G, Lederer H. Fluorometric measurement of triglycerides. In: Skeggs LT, Jr, eds. Automation in Analytical Chemistry: Technicom Symposia. New York, NY: Madiad Inc; 1965:341-344.
35. Allain CC, Poon LS, Chan GSG, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem. 1974;20:470-475.
36. Freidewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein-cholesterol in plasma without the use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
37. Guo H, Chapman MJ, Bruckert E, Farriaux JP, De Gennes JL. Lipoprotein Lp(a) in homozygous familial hypercholesterolemia: density profile, particle heterogeneity and apolipoprotein(a) phenotype. Atherosclerosis. 1991;31:69-83.
38. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC. Measurement of protein using bicinchoninic acid. Anal Biochem. 1985;150: 76-85.
39. Roeschlau P, Bernt E, Gruber W. Enzymatische bestimmung des gesamt-cholesterins im serum. Klin Chem Klin Biochem. 1974;12:226-231.
40. Takayama M, Itoh S, Nagasaki T, Tanimizu I. A new enzymatic method for determination of serum choline-containing phospholipids. Clin Chim Acta. 1977;79:93-98.
41. Biggs HC, Erickson JM, Moorehead R. A manual colorimetric assay of triglycerides in serum. Clin Chem. 1975;21:437-450.
42. Arnaud J, Fortis I, Blachier S, Kia D, Favier A. A simultaneous determination of retinol, α-tocopherol and β-carotene in serum by isocratic high performance liquid chromatography. J Chromatogr. 1991;572: 103-116.
43. Yamamoto, Brodsky MH, Baker JC, Ames BN. Detection and characterization of lipid hydroperoxides at picomole levels by high-performance liquid chromatography. Anal Biochem. 1987;160:146-150.
44. Laureaux C, Therond P, Bonnefont-Rousselot D, Troupel SE, Legrand A, Delattre J. α-Tocopherol enrichment of high density lipoproteins: stabilization of hydroperoxides produced during copper oxidation. Free Radic Biol Med. 1997;22:185-194.
45. Therond P, Couturier M, Demelier JF, Lemonnier F. Simultaneous determination of the main molecular species of soybean phosphatidylcholine or phosphatidylethanolamine and their corresponding hydroperoxides obtained by lipoxygenase treatment. Lipids. 1993;28:245-249.
46. Esterbauer H, Gebicki J, Puhl H, Jürgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med. 1992;13:341-390.
47. Kontush A, Hübner C, Finckh B, Kohlschütter A, Beisiegel U. How different constituents of low density lipoprotein determine its oxidizability by copper: a correlational approach. Free Radic Res. 1995;24: 135-147.
48. Dieber-Rotheneder M, Puhl H, Waeg G, Striegl G, Esterbauer H. Effect of oral supplementation with D-α-tocopherol on the vitamin E content of human low density lipoproteins and resistance to oxidation. J Lipid Res. 1991;33:899-906.
49. Halliwell B. Oxidation of low-density lipoproteins: questions of initiation, propagation, and the effect of antioxidants. Am J Clin Nutr. 1995;61:670S-677S.
50. Jialal I, Grundy SM. Effect of dietary supplementation with α-tocopherol on the oxidative modification of low density lipoprotein. J Lipid Res. 1992;33:899-906.
51. Babiy AV, Gekicki JM, Sullivan DR. Vitamin E content and low density lipoprotein oxidizability induced by free radicals. Atherosclerosis. 1990; 81:175-182.
52. Croft KD, Williams P, Dimmit S, Abu-Amsha R, Beitin LJ. Oxidation of low density lipoprotein: effect of antioxidant content, fatty acid composition and intrinsic phospholipase activity on susceptibility to metal ion-induced oxidation. Biochim Biophys Acta. 1995;1254:250-256.
53. Upston JM, Neuzil J, Stocker R. Oxidation of LDL by recombinant human 15-lipoxygenase: evidence for α-tocopherol-dependent oxidation of esterified core and surface lipids. J Lipid Res. 1996;37:2650-2661.
54. Neuzil J, Thomas SR, Stocker R. Requirement for, promotion, or inhibition by α-tocopherol of radical-induced initiation of plasma lipoprotein lipid peroxidation. Free Radic Biol Med. 1997;22:57-71.
55. Berlin E, Judd JT, Marshall MW, Kliman PG. Dietary linoleate increases fluidity and influences chemical composition of plasma low density lipoprotein in adult men. Atherosclerosis. 1987;66:215-225.
56. Smith LL. Another cholesterol hypothesis: cholesterol as antioxidant. Free Radic Biol Med. 1991;11:47-61.
57. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, Navab M. Protective effect of high density lipoprotein associated paraoxonase. J Clin Invest. 1995;96:2882-2891.
58. Tselepis AD, Dentan C, Karabina SAP, Chapman MJ, Ninio E. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Arterioscler Thromb Vasc Biol. 1995;15: 1764-1773.
59. Dentan C, Tselepis AD, Chapman MJ, Ninio E. Pefabloc, 4-[2-aminoethyl]benzenesulfonyl fluoride, is a new, potent nontoxic and irreversible inhibitor of PAF-degrading acetylhydrolase. Biochim Biophys Acta. 1996;1299:353-357.
60. Sattler W, Christison J, Stocker R. Cholesterylester hydroperoxide reducing activity associated with isolated high-and low-density lipoprotein. Free Radic Biol Med. 1995;18:421-429.
61. McNamara JR, Small DM, Li Z, Schaefer EJ. Difference in LDL subspecies involves alterations in lipid composition and conformational changes in apolipoprotein B. J Lipid Res. 1996;37:1924-1935.
62. Chi Chen G, Liu W, Duchateau P, Allaart J, Hamilton RL, Mendel C, Lau K, Hardman DA, Frost PH, Malloy MJ, Kane JP. Conformational differences inhuman apolipoprotein B-100 among subspecies of low density lipoproteins (LDL). J Biol Chem. 1994;269:29121-29128.
63. Lund-Katz S, Lapland PM, Phillips MC, Chapman MJ. Apolipoprotein B-100 conformation and particle surface charge in human LDL subspecies: implication for LDL receptor interaction. Biochemistry. 1998;37: 12867-12874.
64. Fruebis J, Parthasarathy S, Steinberg D. Evidence for a concerted reaction between lipid hydroperoxides and polypeptides. Proc Natl Acad Sci U S A. 1992;89:10588-10592.
65. Iio T, Yoden K. Fluorescence formation from hydroperoxide of phosphatidylcholine with amino compound. Lipids. 1988;23:65-67.
66. Tanfani F, Galleazzi T, Curatola G, Bertoli E, Feretti G. Reduced β-strand content in apoprotein B100 in smaller and dense low density lipoprotein subclasses as probed by Fourier-transform infrared spectroscopy. Biochem J. 1997;322:765-769.